Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1

被引:281
作者
Moore, PL
Crooks, ET
Porter, L
Zhu, P
Cayanan, CS
Grise, H
Corcoran, P
Zwick, MB
Franti, M
Morris, L
Roux, KH
Burton, DR
Binley, JM
机构
[1] Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA
[2] Natl Inst Communicable Dis, Johannesburg, South Africa
[3] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA
[4] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA
[5] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[6] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[7] Progen Pharmaceut Inc, Tarrytown, NY 10591 USA
关键词
D O I
10.1128/JVI.80.5.2515-2528.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type I (HIV-1) neutralizing antibodies are thought be distinguished from nonneutralizing antibodies by their ability to recognize functional gp120/gp41 envelope glycoprotein (Env) trimers. The antibody responses induced by natural HIV-1 infection or by vaccine candidates tested to date consist largely of nonneutralizing antibodies. One might have expected a more vigorous neutralizing response, particularly against virus particles that bear functional trimers. The recent surprising observation that nonneutralizing antibodies can specifically capture HIV-1 may provide a clue relating to this paradox. Specifically, it was suggested that forms of Env, to which nonneutralizing antibodies can bind, exist on virus surfaces. Here, we present evidence that HIV-1 particles bear nonfunctional gp120/gp41 monomers and gp120-depleted gp41 stumps. Using a native electrophoresis band shift assay, we show that antibody-trimer binding predicts neutralization and that the nonfunctional forms of Env may account for virus capture by nonneutralizing antibodies. We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization.
引用
收藏
页码:2515 / 2528
页数:14
相关论文
共 74 条
  • [31] Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
    Herrera, C
    Spenlehauer, C
    Fung, MS
    Burton, DR
    Beddows, S
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (02) : 1084 - 1091
  • [32] Involvement of FcγR I (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages
    Holl, V
    Hemmerter, S
    Burrer, R
    Schmidt, S
    Bohbot, A
    Aubertin, AM
    Moog, C
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (10) : 6274 - 6283
  • [33] Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
    Kolchinsky, P
    Kiprilov, E
    Sodroski, J
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (05) : 2041 - 2050
  • [34] Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-Infected lymphocytes
    Kuznetsov, YG
    Victoria, JG
    Robinson, WE
    McPherson, A
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (22) : 11896 - 11909
  • [35] Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
    Kwong, PD
    Wyatt, R
    Sattentau, QJ
    Sodroski, J
    Hendrickson, WA
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (04) : 1961 - 1972
  • [36] HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Kwong, PD
    Doyle, ML
    Casper, DJ
    Cicala, C
    Leavitt, SA
    Majeed, S
    Steenbeke, TD
    Venturi, M
    Chaiken, I
    Fung, M
    Katinger, H
    Parren, PWLH
    Robinson, J
    Van Ryk, D
    Wang, LP
    Burton, DR
    Freire, E
    Wyatt, R
    Sodroski, J
    Hendrickson, WA
    Arthos, J
    [J]. NATURE, 2002, 420 (6916) : 678 - 682
  • [37] Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gpl120 is sterically restricted on primary human immunodeficiency virus type 1
    Labrijn, AF
    Poignard, P
    Raja, A
    Zwick, MB
    Delgado, K
    Franti, M
    Binley, J
    Vivona, V
    Grundner, C
    Huang, CC
    Venturi, M
    Petropoulos, CJ
    Wrin, T
    Dimitrov, DS
    Robinson, J
    Kwong, PD
    Wyatt, RT
    Sodroski, J
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (19) : 10557 - 10565
  • [38] Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
    Lifson, JD
    Rossio, JL
    Piatak, M
    Bess, J
    Chertova, E
    Schneider, DK
    Coalter, VJ
    Poore, B
    Kiser, RF
    Imming, RJ
    Scarzello, AJ
    Henderson, LE
    Alvord, WG
    Hirsch, VM
    Benveniste, RE
    Arthur, LO
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (07) : 772 - 787
  • [39] Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
    Lusso, P
    Earl, PL
    Sironi, F
    Santoro, F
    Ripamonti, C
    Scarlatti, G
    Longhi, R
    Berger, EA
    Burastero, SE
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (11) : 6957 - 6968
  • [40] Rabies virus glycoprotein can fold in two alternative, antigenically distinct conformations depending on membrane-anchor type
    Maillard, AP
    Gaudin, Y
    [J]. JOURNAL OF GENERAL VIROLOGY, 2002, 83 : 1465 - 1476